Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 4, 2007, Pages 539-546

  Park, H J ^a   Shinn, H K ^a   Ryu, S H ^a   Lee, H S ^a   Park, C S ^b   Kang, J H ^b  

^a Inha University Hospital   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BUPIVACAINE; FENTANYL; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ABCB1 GENE; ADULT; AGED; ALLELE; ANALYSIS OF VARIANCE; ARTICLE; BISPECTRAL INDEX; BREATHING RATE; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; FEMALE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; KOREA; LUNG VENTILATION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OXYGEN SUPPLY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL ANESTHESIA; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANESTHESIA, SPINAL; ANESTHETICS, INTRAVENOUS; ELECTROCARDIOGRAPHY; FEMALE; FENTANYL; GENOTYPE; HAPLOTYPES; HUMANS; KOREA; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; OXYGEN CONSUMPTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RESPIRATORY MECHANICS;

EID: 33947391399     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100046     Document Type: Article

References (39)

1. Lown, K.S. et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248-260 (1997).
2. Greiner, B. et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104, 147-153 (1999).
3. Schinkel, A.H., Wagenaar, E., Mol, C.A. & van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97, 2517-2524 (1996).
4. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I. & Willingham, M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84, 7735-7738 (1987).
5. Tanabe, M. et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 297, 1137-1143 (2001).
6. Schinkel, A.H. et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 (1994).
7. Schinkel, A.H., Wagenaar, E., van Deemter, L., Mol, C.A. & Borst, P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96, 1698-1705 (1995).
8. van Asperen, J., Schinkel, A.H., Beijnen, J.H., Nooijen, W.J., Borst, P. & van Tellingen, O. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice. J. Natl. Cancer Inst. 88, 994-999 (1996).
9. Dagenais, C., Graff, C.L. & Pollack, G.M. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem. Pharmacol. 67, 269-276 (2004).
10. Cutler, L., Howes, C., Deeks, N.J., Buck, T.L. & Jeffrey, P. Development of a P-glycoprotein knockout model in rodents to define species differences in its functional effect at the blood-brain barrier. J. Pharm. Sci. 95, 1944-1953 (2006).
11. Hsiao, P. et al. Verapamil P-glycoprotein transport across the rat blood-brain barrer; cyclosporine, a concentration inhibition analysis, and comparison with human data. J. Pharmacol. Exp. Ther. 317, 704-710 (2006).
12. Takeuchi, T. et al. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm. Res. 23, 1460-1472 (2006).
13. Sakaeda, T., Nakamura, T. & Okumura, K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4, 397-410 (2003).
14. Eichelbaum, M., Fromm, M.F. & Schwab, M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26, 180-185 (2004).
15. Hoffmeyer, S. et al. Functional polymorphisms of the human multidrug resistance gene: multiple, sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478 (2000).
16. Coulbault, L. et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 79, 316-324 (2006).
17. Sadeque, A.J., Wandel, C., He, H., Shar, S. & Wood, A.J. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68, 231-237 (2000).
18. Thompson, S.J., Koszdin, K. & Bernards, C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92, 1392-1399 (2000).
19. Kharasch, E.D., Hoffer, C., Altuntas, T.G. & Whittington, D. Quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl. J. Clin. Pharmacol. 44, 224-233 (2004).
20. Henthorn, T.K., Liu, Y., Mahapatro, M. & Ng, K.Y. Active transport of fentanyl by the blood-brain barrier. J. Pharmacol. Exp. Ther. 289, 1084-1089 (1999).
21. Cirella, V.N., Pantuck, C.B., Lee, Y.J. & Pantuck, E.J. Effects of cyclosporine on anesthetic action. Anesth. Analg. 66, 703-706 (1987).
22. Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J.H., Borst, P. & Schinkel, A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100, 2430-2436 (1997).
23. Yamazaki, M. et al. In vitro substrate identification studies for P-glycoprotein-mediated transport: species differences and predictability of in vivo results. J. Pharmacol. Exp. Ther. 296, 723-735 (2001).
24. Tang, K. et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12, 437-450 (2002).
25. Yi, S.Y. et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. 76, 418-427 (2004).
26. Saito, K. et al. Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. Clin. Biochem. 36, 511-518 (2003).
27. Lee, S.S. et al. MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. Ther. Drug Monit. 27, 531-535 (2005).
28. Schleimer, R., Benjamini, E., Eisele, J. & Henderson, G. Pharmacokinetics of fentanyl as determined by radioimmunoassay. Clin. Pharmacol. Ther. 23, 188-194 (1978).
29. McClain, D.A. & Hug, C.C. Jr. Intravenous fentanyl kinetics. Clin. Pharmacol. Ther. 28, 106-114 (1980).
30. Mather, L.E. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin. Pharmacokinet. 8, 422-446 (1983).
31. Pauli-Magnus, C., Feiner, J., Brett, C., Lin, E. & Kroetz, D.L. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin. Pharmacol. Ther. 74, 487-498 (2003).
32. Greenwald, S., Chiang, H.H., Devlin, P., Smith, C., Sigl, J. & Chamoun, N. Bispectral index (BIS2.0) as a hypnosis measure (abstract). Anesthesiology 81, A477 (1994).
33. Lui, J., Singh, H. & White, P.F. Electroencephalogram bispectral analysis predicts the depth of midazolam-induced sedation. Anesthesiology 84, 64-69 (1996).
34. Sandlin, D. A closer look at bispectral index monitoring. J. Perianesth. Nurs. 16, 420-422 (2001).
35. Glass, P.S., Bloom, M., Kearse, L., Rosow, C., Sebel, P. & Manberg, P. Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. Anesthesiology 86, 836-847 (1997).
36. Lysakowski, C., Dumont, L., Pellegrini, M., Clergue, F. & Tassonyi, E. Effects of fentanyl, alfentanil, remifentanil and sufentanil on loss of consciousness and bispectral index during propofol induction of anesthesia. Br. J. Anesth. 86, 523-527 (2001).
37. Bell, J.K., Laasch, H.U., Wilbraham, L., England, R.E., Morris, J.A. & Martin, D.F. Bispectral index monitoring for conscious sedation in intervention: better, safer, faster. Clin. Radiol. 59, 1106-1113 (2004).
38. Marzolini, C., Paus, E., Buclin, T. & Kim, R.B. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33 (2004).
39. Cascorbi, I. et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69, 169-174 (2001).